MET and neoplasm: Amivantamab has shown anti-tumor activity across diverse EGFR-driven and MET-driven NSCLC28,29, with a tolerable safety profile, and is approved for the treatment of patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, whose disease progressed on or after platinum-based chemotherapy28,30–32.